Murphy, F., Church, D., Medley, L., Davies, J., Breen, D., Clelland, C., . . . Talbot, D. (2011). PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.
Chicago Style (17th ed.) CitationMurphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.
MLA (9th ed.) CitationMurphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.
Warning: These citations may not always be 100% accurate.